



Strategy Certificates

Linked to the Zuger Kantonalbank Selektion Aktien Schweiz
Issued by UBS AG, Zurich

Cash settled
SVSP Product Type: Tracker Certificates (1300, callable)
Valor: 25879570

Final Terms

This Product does not represent a participation in any of the collective investment schemes pursuant to Art. 7 ff of the Swiss Federal Act on Collective Investment Schemes (CISA) and thus does not require an authorisation of the Swiss Financial Market Supervisory Authority (FINMA). Therefore, investors in this Product are not eligible for the specific investor protection under the CISA.

1. Description of the Product

Information on Underlying

The Strategy Certificate linked to the **Zuger Kantonalbank Selektion Aktien Schweiz** enables the investor to participate at the total return (capital appreciation and dividends) of a selected basket of Swiss stocks.

Underlying(s)	Description
Zuger Kantonalbank Selektion Aktien Schweiz (the "Reference-Portfolio")	Zuger Kantonalbank Selektion Aktien Schweiz (the "Reference-Portfolio") is a notional Swiss Franc ("CHF") denominated actively managed Reference-Portfolio, created and maintained by Zuger Kantonalbank AG (the "Reference-Portfolio Advisor"). The Reference-Portfolio aims to replicate (i) the performance of a basket of Swiss stocks (each a "Constituent" and together the "Equity Position" or "Constituents"), and (ii) from time to time, a cash position (the "Cash Position", which together with the Constituents shall be referred to as the "Reference-Portfolio Components"), less fees and costs. The Reference-Portfolio Advisor maintains the Reference-Portfolio in accordance with the attached Reference-Portfolio Guidelines (Annex). No interest will be paid on the Cash Position.

Product Details

Security Numbers	Valor: 25879570 / ISIN: CH0258795704
Issue Size	Up to 50'000 Units (with reopening clause)
Initial Reference-Portfolio Level	CHF 1'000.00
Issue Price	CHF 1'000.00 (100.00% of Initial Reference-Portfolio) (unit quotation)
Settlement Currency	CHF

Dates

Launch Date	17 November 2014
Pricing Date ("Pricing")	28 November 2014 to 02 December 2014

Contact: UBS AG, P.O. Box, 8098 Zürich	Private Investors: Please contact your client advisor or send an email to keyinvest@ubs.com
Internet: www.ubs.com/keyinvest	Product Hotline: +41-44-239 76 76*

Investors outside of Switzerland should consult their local client advisors.
Please note that calls made to the numbers marked with an asterisk (*) may be recorded. Should you call one of these numbers, we shall assume that you consent to this business practice.

Issue Date / Payment Date	05 December 2014
Last Trading Day	29 November 2021
Expiration Date	29 November 2021 (subject to Market Disruption Events, Early Termination and Unwind Disruption provisions), extendable at the option of the Issuer for additional 7 years periods, on a rolling basis, with a notice period of 180 calendar days. In case of an extension, an investor can with a notice period of 90 days prior to the Expiration Date request from the Issuer in writing that his Products are redeemed at the Redemption Date following the original Expiration Date. In case this is not a Business Day, the next following Business Day will apply. For the avoidance of doubt: Such request of redemption shall be possible after each extension of the term.
Redemption Date	5 Business Days following the Expiration Date (currently expected to be 06 December 2021) or the Early Termination Date (as applicable) (in any case subject to Market Disruption Event provisions).
Closing Date (for Swiss tax purposes)	1 January, for the first time 1 January 2015

Redemption

Redemption Amount	The investor is entitled to receive from the Issuer on the Redemption Date an amount in the Settlement Currency equal to the Reference-Portfolio Level on the Expiration Date or the Early Termination Date, as applicable, as calculated by the Calculation Agent.
-------------------	---

In the event that a notional investor (in the same position as the Issuer) would be unable to unwind its investments in the Reference-Portfolio Constituents by the Expiration Date, the Early Termination Date, the Automatic Early Termination Date or the Automatic Stop Loss Redemption Date (as applicable) (such event a "Unwind Disruption"), the Issuer reserves the right to extend the Expiration Date or Early Termination Date, as applicable, to such date where a notional investor in the Reference-Portfolio Constituents is able to fully unwind the Reference-Portfolio Components in cash.

Please note that the Redemption Amount may be less than the initially invested capital.

Early Termination by Issuer	The Issuer is entitled to early terminate the Product in full subject to the following notice period:
-----------------------------	---

Quarterly, i.e. as of each 31 March, 30 June, 30 September and 31 December (the "**Early Termination Date**") subject to at least 45 Business Days prior notice being given to the investors. The first possible Early Redemption Date will be 31 March 2015.

Should Zuger Kantonalbank cease to be or to act as the Reference-Portfolio Advisor, the Products will be early terminated by the Issuer as of the first Early Termination Date on which Zuger Kantonalbank no longer is or acts as the Reference-Portfolio Advisor, as determined at the reasonable discretion of the Calculation Agent. No notice period shall apply in that case.

There is no Early Termination right for the investor in this Product.

Reference-Portfolio Level	<p>Sum of all Reference-Portfolio Components taking into consideration their respective weightings whereby the Equity Position is valued at the closing price published by the related exchange. The calculation also takes into account the effect of all fees and costs associated with the Reference-Portfolio. The Reference-Portfolio Level is calculated for each Business Day by the Calculation Agent on the next Business Day.</p> <p>If a Business Day is not a Component Business Day for any Reference-Portfolio Constituent, then the price for such Reference-Portfolio Constituent used to calculate the Reference-Portfolio Level will be the price of the previous Component Business Day for such Reference-Portfolio Constituent.</p>
Dividends	<p>Any amounts reflecting net dividends of the Reference-Portfolio Constituents will be re-invested in the Reference-Portfolio.</p>

Product Structure

The Product allows for participation in the performance of the Reference-Portfolio. The Reference-Portfolio is a notional actively managed portfolio, created and maintained by the Reference-Portfolio Advisor. The Reference-Portfolio aims to replicate the performance of a basket Swiss stocks and, from time to time, a cash position, less fees and costs. Any amounts reflecting dividends of the Reference-Portfolio Constituents will be re-invested into the Reference-Portfolio.

Contact: UBS AG, P.O. Box, 8098 Zürich

Internet: www.ubs.com/keyinvest

Private Investors: Please contact your client advisor or send an email to keyinvest@ubs.com

Product Hotline: +41-44-239 76 76*

Investors outside of Switzerland should consult their local client advisors.
Please note that calls made to the numbers marked with an asterisk (*) may be recorded. Should you call one of these numbers, we shall assume that you consent to this business practice.

General Information

Issuer	UBS AG, Zurich
Issuer Rating	A2 Moody's / A S&P's / A Fitch
Lead Manager	UBS AG, Zurich (UBS Investment Bank)
Calculation Agent	UBS AG, London Branch
Paying Agent	UBS AG, Zurich
Listing	Not Applicable
Reference-Portfolio Advisor	Zuger Kantonalbank AG, Zug "Please note that the Reference Portfolio Advisor may not only act as Reference Portfolio Advisor with regard to the Reference Portfolio, but may at the same time act as asset manager or financial consultant with regard to investors in the Certificates, which may induce potential conflicts between investors' interests and Reference Portfolio Advisor's interests, especially in case the Reference Portfolio Advisor receives part of the Management Fee. The Reference Portfolio Advisor has implemented any measures required to fully mitigate such potential conflict of interest."
Business Days	Any days on which banks in London, Frankfurt a.M., Zurich, Hong Kong and New York are open for business.
Component Business Day	In respect of any Constituent means, a day on which (i) the Exchange and Related Exchange are scheduled to be open for trading, notwithstanding any day on which they close for business prior to their regular weekday closing time and (ii) the Calculation Agent is open for business.
Exchange	The primary stock exchange on which the stock is listed and publicly quoted and traded, as determined by the Calculation Agent from time to time.
Related Exchange	Means the principal exchange (if any) on which options or future contracts relating to the stock/index are traded or quoted, as determined by the Calculation Agent.
Liquidity	UBS intends to offer daily bid/offer prices depending on size, market conditions such as liquidity in the markets of the Reference-Portfolio Components.
Reference-Portfolio fees (calculated daily)	Quarterly fee of 0.325% (1.30% per year) of the Reference-Portfolio Level accrued on a daily basis, and the Adjustment Fee, charged by the Calculation Agent and deducted from the Reference-Portfolio Level. Apart of the Reference-Portfolio Fees will be used to compensate the Reference Portfolio Advisor.
Rebalancing	Rebalancing means any change in the Reference-Portfolio Components by the Reference-Portfolio Advisor after the Issue Date. The Calculation Agent has the right to reject Rebalancings under specific circumstances. The expected number of Rebalancings per year is 12. In case of a Rebalancing, secondary market trading of the Product will be suspended until completion of the Rebalancing.
Rebalancing / Adjustment Fee	There will be no adjustment fee charged up to 12 rebalancings per year. Over and above, each additional rebalancing is subject to an Adjustment Fee which is levied for each adjustment made in the Reference-Portfolio, and represents a percentage of the notional volume of each of the purchase and/or sale of a Constituent. The Adjustment Fee equals 0.10%.
Minimum Investment	1 Unit(s)
Minimum Trading Lot	1 Unit(s)
Clearing	SIX SIS, Euroclear, Clearstream (registered as intermediated securities with SIX SIS AG, in Switzerland)

Contact: UBS AG, P.O. Box, 8098 Zürich

Internet: www.ubs.com/keyinvest

Private Investors: Please contact your client advisor or send an email to keyinvest@ubs.com

Product Hotline: +41-44-239 76 76*

Investors outside of Switzerland should consult their local client advisors.

Please note that calls made to the numbers marked with an asterisk (*) may be recorded. Should you call one of these numbers, we shall assume that you consent to this business practice.

Form of deed	Uncertificated Securities
Governing Law / Jurisdiction	Switzerland / Zurich
Adjustments	The terms of the Product may be subject to adjustments during its lifetime. Detailed information on such adjustments is to be found in the Product Documentation.

Tax Treatment Switzerland

Swiss Federal Stamp Duty	The product is not subject to Swiss Federal Stamp Duty.
Swiss Federal Income Tax	The taxable income and capital gains/losses will be kept apart and will be reported to the Swiss Federal Tax Administration annually. Taxable income is subject to Swiss Federal, cantonal and communal income tax.
Swiss Withholding Tax	The product is not subject to the Swiss withholding tax.
EU Savings Tax Treatment	For Swiss paying agents, the product is not subject to the EU Savings tax.

The tax information only provides a general overview of the potential tax consequences linked to this product at the time of issue. Tax laws and tax doctrine may change, possibly with retroactive effect.

Product Documentation

This document ("**Final Terms**") constitutes the Simplified Prospectus for the Product and contains the information required by Article 5 CISA and the corresponding Guidelines of the Swiss Bankers Association. The prospectus requirements of Article 652a/Article 1156 of the Swiss Code of Obligations are not applicable.

These Final Terms (Simplified Prospectus) together with the 'General Terms and Conditions for Structured Products on Equity, Commodity and Index Underlyings', stipulated in English and as amended from time to time ("**General Terms and Conditions**") shall form the entire documentation for this Product ("**Product Documentation**"), and accordingly the Final Terms should always be read together with the General Terms and Conditions. The Simplified Prospectus may be provided in various languages, however, only the English version will be relevant and any translations are for convenience only. Definitions used in the Final Terms, but not defined therein shall have the meaning given to them in the General Terms and Conditions. In the event that the Product is listed (see above item 'Listing' under «General Information»), the Product Documentation will be amended in accordance with the listing requirements of the relevant exchange.

The Product Documentation can be obtained free of charge from UBS AG, P.O. Box, CH-8098 Zurich (Switzerland), via telephone (+41-(0)44-239 47 03), fax (+41-(0)44-239 69 14) or via e-mail (swiss-prospectus@ubs.com). In addition, for clients outside of the United Kingdom, the Product Documentation is available on the internet at www.ubs.com/keyinvest. Notices in connection with this Product shall be validly given by publication as described in the General Terms and Conditions. Furthermore, for clients outside of the United Kingdom, any changes with regard to the terms of this Product shall be published on the internet at www.ubs.com/keyinvest.

Classification

This Product does not represent a participation in any of the collective investment schemes pursuant to Art. 7 ff of the Swiss Federal Act on Collective Investment Schemes (CISA) and thus does not require an authorisation of the Swiss Financial Market Supervisory Authority (FINMA). Therefore, investors in this Product are not eligible for the specific investor protection under the CISA.

Furthermore, this Product does not benefit from any depositor protection under Art. 37b under the Swiss Federal Law on Banks and Savings Banks (Banking Act) or other forms of deposit insurance under any other law as might be applicable to this Product.

Prudential Supervision

UBS AG is authorised and regulated by the Swiss Financial Market Supervisory Authority (FINMA). In addition, its London Branch is authorised by the Prudential Regulation Authority and subject to regulation by the Financial Conduct Authority and limited regulation by the Prudential Regulation Authority and its Jersey Branch is authorised and regulated by the Jersey Financial Services Commission (JFSC).

Contact: UBS AG, P.O. Box, 8098 Zürich

Internet: www.ubs.com/keyinvest

Private Investors: Please contact your client advisor or send an email to keyinvest@ubs.com

Product Hotline: +41-44-239 76 76*

Investors outside of Switzerland should consult their local client advisors.

Please note that calls made to the numbers marked with an asterisk (*) may be recorded. Should you call one of these numbers, we shall assume that you consent to this business practice.

2. Prospects of Profits and Losses

Market Expectation	Investors expect negative and positive performance in a basket of stocks over the life of the Product.
Risk Tolerance	<p>Investors should be experienced investors and familiar with both derivative products and the stock markets.</p> <p>The investors must be willing to make an investment that is fully exposed to the performance of the underlying, meaning that investors might lose their whole investment in the Product in the worst case.</p> <p>The Reference-Portfolio may contain Reference-Portfolio Components denominated in currencies other than the Settlement Currency. The currency risk is not hedged.</p>
Profit Potential	<p>The Product allows for participation in positive performance of the Underlying, as adjusted by various fees and costs as described in more detail above.</p> <p>Furthermore, if prior to the Expiration Date / Early Termination Date /Automatic Early Termination Date / Automatic Stop Loss Redemption Date the Investor decides to buy/sell the Product under the Secondary Market terms (as detailed above), the Investor may also be exposed to any funding costs of the Issuer (including, but not limited to, any internal funding costs whether caused by changes in UBS's credit status or otherwise) in relation to the Product.</p>
Loss Potential	<p>The Investors may lose some or all of the investment as they are exposed to the negative performance of the Underlying. Investors are further exposed to currency risk, as the currency risk is only partially hedged.</p> <p>The Issuer is entitled to redeem the Product early. Moreover the Product will be redeemed automatically in case of a Stop Loss Event.</p>

3. Significant Risks for Investors

For product specific risks please see above (2. Prospects of Profits and Losses)

Risk Factors relating to the Issuer

In addition to the market risk with regard to the development of the Underlying, each investor bears the general risk that the financial situation of the Issuer could deteriorate. The Products constitute immediate, unsecured and unsubordinated obligations of the Issuer, which, particularly in case of insolvency of the Issuer, rank pari passu with each and all other current and future unsecured and unsubordinated obligations of the Issuer, with the exception of those that have priority due to mandatory statutory provisions. The general assessment of the Issuer's creditworthiness may affect the value of the Products. This assessment generally depends on the ratings assigned to the Issuer or its affiliated companies by rating agencies such as Moody's, Fitch and Standard & Poor's.

The Issuer Ratings indicated in this document reflect the situation at the time of issuance and may be subject to changes. The actual Issuer Ratings at any given time can be seen on the Issuer's website (www.ubs.com) under "Analysts & Investors".

Contact:	UBS AG, P.O. Box, 8098 Zürich	Private Investors: Please contact your client advisor or send an email to keyinvest@ubs.com
Internet:	www.ubs.com/keyinvest	Product Hotline: +41-44-239 76 76*

Investors outside of Switzerland should consult their local client advisors.
Please note that calls made to the numbers marked with an asterisk (*) may be recorded. Should you call one of these numbers, we shall assume that you consent to this business practice.

Secondary Market

The Issuer or the Lead Manager, as applicable, intends, under normal market conditions, to provide bid and offer prices for this Product on a regular basis. However, the Issuer or the Lead Manager, as applicable, makes no firm commitment to provide liquidity by means of bid and offer prices for this Product, and assumes no legal obligation to quote any such prices or with respect to the level or determination of such prices. Potential Investors therefore should not rely on the ability to sell this Product at a specific time or at a specific price.

In special market situations, where the Issuer is completely unable to enter into hedging transactions, or where such transactions are very difficult to enter into, the spread between the bid and offer prices may be temporarily expanded, in order to limit the economic risks of the Issuer.

Market Risk

The investor is exposed to market disruption events (such as trading disruption, exchange disruption and early closure of the relevant exchange), adjustments and early termination which could have an impact on the redemption amount through delay in payment or change in value. For a detailed description of such events and their effects please read the Final Terms and the General Terms and Conditions.

Important Information

This information is communicated by UBS AG and/or its affiliates ("UBS"). UBS may from time to time, as principal or agent, have positions in, or may buy or sell, or make a market in any securities, currencies, financial instruments or other assets underlying the transaction to which this document relates. UBS may provide investment banking and other services to and/or have officers who serve as directors of the companies referred to in this document. UBS' trading and/or hedging activities related to this transaction may have an impact on the price of the underlying asset and may affect the likelihood that any relevant barrier is crossed. UBS has policies and procedures designed to minimise the risk that officers and employees are influenced by any conflicting interest or duty and that confidential information is improperly disclosed or made available.

In certain circumstances UBS sells this Product to dealers and other financial institutions at a discount to the issue price or rebates to them for their account some proportion of the issue price. Further information is available on request.

Structured transactions are complex and may involve a high risk of loss. Prior to entering into a transaction you should consult with your own legal, regulatory, tax, financial and accounting advisors to the extent you consider it necessary, and make your own investment, hedging and trading decisions (including decisions regarding the suitability of this transaction) based upon your own judgement and advice from those advisers you consider necessary. Save as otherwise expressly agreed in writing, UBS is not acting as your financial adviser or fiduciary in any transaction.

This document should not be construed as an offer, personal recommendation or solicitation to conclude a transaction and should not be treated as giving investment advice. The terms of any investment will be exclusively subject to the detailed provisions, including risk considerations, contained in the Information Memorandum, Prospectus or other issuer documentation for the issue of the Products/Notes (the "Prospectus").

UBS makes no representation or warranty relating to any information herein which is derived from independent sources. This document shall not be copied or reproduced without UBS' prior written permission.

No action has been or will be taken in any jurisdiction that would permit a public offering of the Products described herein, save where explicitly stated in the Product Documentation. The Products must be sold in accordance with all applicable selling restrictions in the jurisdictions in which they are sold.

There is a possibility that costs, including taxes, related to transactions in connection with this Product may arise for the Investor that are not paid by UBS or imposed by it.

Contact:	UBS AG, P.O. Box, 8098 Zürich	Private Investors: Please contact your client advisor or send an email to keyinvest@ubs.com
Internet:	www.ubs.com/keyinvest	Product Hotline: +41-44-239 76 76*

Investors outside of Switzerland should consult their local client advisors.
Please note that calls made to the numbers marked with an asterisk (*) may be recorded. Should you call one of these numbers, we shall assume that you consent to this business practice.

Selling Restrictions

Any Products purchased by any person for resale may not be offered in any jurisdiction in circumstances which would result in the Issuer being obliged to register any further documentation relating to this Product in such jurisdiction.

The restrictions listed below must not be taken as definitive guidance as to whether this Product can be sold in a jurisdiction. Additional restrictions on offering, selling or holding of this Product may apply in other jurisdictions. Investors in this Product should seek specific advice before on-selling this Product.

Europe - Any public offer of this Product within a EEA jurisdiction (EU member states plus Norway, Iceland and Liechtenstein) shall only be possible if compliant with the requirements of the EUPD and with the law of that jurisdiction.

If the prospectus either does not qualify as a prospectus published in accordance with the requirements of the EUPD or is not filed with or notified to the relevant Financial Supervisory Authority, this Product may not be offered or sold in EEA jurisdictions other than 1) in minimum denominations of, or total consideration per investor of at least, EUR 50,000 (or equivalent in other currencies), provided that the offer is only being made in one or more EEA jurisdiction that will not, before the end of the offer period for the Notes, have implemented the provision under the Directive 2010/73/EU (the "PD Amending Directive") that increases this minimum denomination (or total consideration per investor) to EUR 100,000; or 2) only to Qualified Investors; and/or (aggregated for all distributors) to less than 100 or, if the relevant EEA jurisdiction has implemented the relevant provision of the 2010 PD Amending Directive, 150 natural or legal persons that are not Qualified Investors per EEA jurisdiction. "Qualified Investors" are persons or entities as defined in the Prospectus Directive.

For information on public offering in EEA jurisdictions please see under section "General Information" above.

Hong Kong – Each purchaser has represented and agreed that it has not issued or had in its possession for the purposes of issue, and will not issue or have in its possession for the purposes of issue, whether in Hong Kong or elsewhere, any advertisement, invitation or document relating to the Products, which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to Products which are or are intended to be disposed of only to persons outside Hong Kong or only to "professional investors" as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance.

This is a structured product which involves derivatives. Do not invest in it unless you fully understand and are willing to assume the risks associated with it. If you are in any doubt about the risks involved in the product, you may clarify with the intermediary or seek independent professional advice.

Singapore - This Term Sheet, the Final Terms, the Base Prospectus and the Supplemental Prospectus in respect of the programme under which the Notes would be issued have not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this Term Sheet, the Final Terms, the Base Prospectus, the Supplemental Prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the Notes may not be circulated or distributed, nor may the Notes be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i) to an institutional investor under Section 274 of the Securities and Futures Act, Chapter 289 of Singapore (the "SFA"), (ii) to a relevant person pursuant to Section 275(1), or any person pursuant to Section 275(1A), and in accordance with the conditions specified in Section 275, of the SFA, or (iii) otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA. Where the Notes are subscribed or purchased under Section 275 of the SFA by a relevant person which is:

(a) a corporation (which is not an accredited investor (as defined in Section 4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or
(b) a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited investor,
securities (as defined in Section 239(1) of the SFA) of that corporation or the beneficiaries' rights and interest (howsoever described)

in that trust shall not be transferred within six months after that corporation or that trust has acquired the Notes pursuant to an offer made under Section 275 of the SFA except:

(1) to an institutional investor or to a relevant person defined in Section 275(2) of the SFA, or to any person arising from an offer referred to in Section 275(1A) or Section 276(4)(i)(B) of the SFA;
(2) where no consideration is or will be given for the transfer;
(3) where the transfer is by operation of law;
(4) as specified in Section 276(7) of the SFA; or
(5) as specified in Regulation 32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations 2005 of Singapore

UK – For the purpose of non-discretionary accounts, this Product should not be sold with a consideration of less than 100,000 EUR or equivalent.

USA - This Product may not be sold or offered within the United States or to U.S. persons.

Contact:	UBS AG, P.O. Box, 8098 Zürich	Private Investors: Please contact your client advisor or send an email to keyinvest@ubs.com
Internet:	www.ubs.com/keyinvest	Product Hotline: +41-44-239 76 76*

Investors outside of Switzerland should consult their local client advisors.
Please note that calls made to the numbers marked with an asterisk (*) may be recorded. Should you call one of these numbers, we shall assume that you consent to this business practice.

Annex

Reference-Portfolio Guidelines

Zuger Kantonalbank Selektion Aktien Schweiz

Zuger Kantonalbank Selektion Aktien Schweiz (the "**Reference-Portfolio**") is a notional Swiss Franc ("CHF") denominated actively managed Reference-Portfolio, created and maintained by Zuger Kantonalbank (the "**Reference-Portfolio Advisor**"). The Reference-Portfolio aims to replicate (i) the performance of a basket of Swiss stocks (each a "**Constituent**" and together the "Equity Position" or "Constituents"), and (ii) from time to time, a cash position (the "**Cash Position**", which together with the Constituents shall be referred to as the "**Reference-Portfolio Components**"), less fees and costs. The Reference-Portfolio Advisor maintains the Reference-Portfolio in accordance with the attached Reference-Portfolio Guidelines (Annex). No interest will be paid on the Cash Position.

The Reference-Portfolio Components are selected by the Reference-Portfolio Advisor in accordance with the following guidelines (the "Reference-Portfolio Guidelines"):

1. Only Swiss shares on listed exchanges (the "Investment Universe") with sufficient liquidity may be incorporated as Reference-Portfolio Constituents in the Reference-Portfolio
2. No interest will be paid on the Cash Position of the Reference-Portfolio

In case of a rebalancing the theoretical volume of a buy or sell order for a Constituent is limited to 200% of the average traded daily volume of that Constituent. A rebalancing may happen at the discretion of the Reference-Portfolio Advisor. The theoretical volume is defined as the number of outstanding Certificates multiplied by the Reference-Portfolio Level (using a reasonable foreign exchange rate to convert into the currency of the Constituent) and multiplied by the change in the percentage weight of the Constituent. The average traded daily volume is defined as the 30 Day average trading turnover. The expected number of Rebalancings per year is 12.

At any time, the Reference-Portfolio may reflect a Cash Position which mirrors the holding of cash (the "Cash Position").

Quarterly fee of 0.325% (1.30% per year) of the Reference-Portfolio Level accrued on a daily basis, and the Adjustment Fee, charged by the Calculation Agent and deducted from the Reference-Portfolio Level.

There will be no adjustment fee charged up to 12 rebalancings per year. Over and above, each additional rebalancing is subject to an Adjustment Fee which is levied for each adjustment made in the Reference-Portfolio, and represents a percentage of the notional volume of each of the purchase and/or sale of a Constituent. The Adjustment Fee equals 0.10%.

The above Investment Universe can be amended in agreement between the Calculation Agent and the Reference-Portfolio Advisor.

The Calculation Agent has the right to reject Constituents that form part of a Rebalancing.

The initial Constituents will be:

Side	Name	BBG Code	Price (CHF)	SIB	Weight
Buy	Roche Holding AG	ROG VX	289.4	0.310988252	9.00%
Buy	Novartis AG	NOVN VX	93.5	0.748663102	7.00%
Buy	Nestle SA	NESN VX	72.55	0.689179876	5.00%
Buy	Actelion Ltd	ATLN VX	114.9	0.435161010	5.00%
Buy	Swiss Re AG	SREN VX	82.6	0.544794189	4.50%
Buy	Zurich Insurance Group AG	ZURN VX	302.8	0.115587847	3.50%
Buy	Baloise Holding AG	BALN VX	126.2	0.237717908	3.00%
Buy	Partners Group Holding AG	PGHN SE	277.5	0.108108108	3.00%
Buy	Ams AG	AMS SE	35.83220297	0.837235713	3.00%
Buy	U Blox Holding AG	UBXN SE	139.4604406	0.215114766	3.00%
Buy	UBS Group AG	UBSN VX	17.35	1.440922190	2.50%
Buy	Geberit AG	GEBN VX	336.6	0.074272133	2.50%
Buy	Compagnie Financiere Richemont SA	CFR VX	90.85	0.220143093	2.00%
Buy	Syngenta AG	SYNN VX	318.3	0.062833805	2.00%
Buy	Swisscom AG	SCMN VX	586.5	0.034100597	2.00%
Buy	The Swatch Group SA	UHR VX	477.5	0.041884817	2.00%
Buy	Givaudan SA	GIVN VX	1722	0.011614402	2.00%
Buy	Sonova Holding AG	SOON VX	146.2	0.136798906	2.00%
Buy	Swiss Life Holding AG	SLHN VX	221.4	0.090334237	2.00%
Buy	Lonza Group AG	LONN VX	113.6	0.176056338	2.00%
Buy	Cosmo Pharmaceuticals SpA	COPN SE	151.2250391	0.132253231	2.00%
Buy	Forbo Holding AG	FORN SE	1033.086022	0.019359472	2.00%
Buy	Vaudoise Assurances Holding SA	VAHN SE	433.3486547	0.046152214	2.00%
Buy	Helvetia Holding AG	HELN SE	475	0.042105263	2.00%
Buy	Straumann Holding AG	STMN SE	250	0.080000000	2.00%
Buy	Sika AG	SIK VX	3678	0.002718869	1.00%
Buy	VZ Holding AG	VZN SE	166.8733677	0.059925680	1.00%
Buy	Jungfraubahn Holding AG	JFN SE	78.58060064	0.127257872	1.00%
Buy	Flughafen Zuerich AG	FHZN SE	635	0.015748031	1.00%

Contact: UBS AG, P.O. Box, 8098 Zürich

Internet: www.ubs.com/keyinvest

Private Investors: Please contact your client advisor or send an email to keyinvest@ubs.com

Product Hotline: +41-44-239 76 76*

Investors outside of Switzerland should consult their local client advisors.

Please note that calls made to the numbers marked with an asterisk (*) may be recorded. Should you call one of these numbers, we shall assume that you consent to this business practice.

Side	Name	BBG Code	Price (CHF)	SIB	Weight
Buy	Ascom Holding AG	ASCN SE	15.18087586	0.658723521	1.00%
Buy	Burkhalter Holding AG	BRKN SE	82.07508532	0.121839654	1.00%
Buy	Temenos Group AG	TEMN SE	34.1	0.293255132	1.00%
Buy	Ems Chemie Holding AG	EMSN SE	358.5	0.027894003	1.00%
Buy	Molecular Partners AG	MOLN SE	22.45	0.445434298	1.00%
Buy	APG SGA SA	APGN SE	292.7560976	0.034158127	1.00%
Buy	Emmi AG	EMMN SE	373.5891473	0.026767373	1.00%
Buy	Lem Holding SA	LEHN SE	756.8125	0.013213312	1.00%
Buy	Coltene Holding AG	CLTN SE	64.85826771	0.154182348	1.00%
Buy	MCH Group AG	MCHN SE	63.90019868	0.156494036	1.00%
Buy	Evolva Holding SA	EVE SE	1.32743402	7.533331110	1.00%
Buy	Newron Pharmaceuticals SpA	NWRN SE	24.53439859	0.407590998	1.00%
Buy	Basilea Pharmaceutica AG	BSLN SE	93.2	0.107296137	1.00%
Buy	Orascom Development Holding AG	ODHN SE	19.65602585	0.508749840	1.00%
Buy	Autoneum Holding AG	AUTN SE	168.2087413	0.059449943	1.00%
Buy	Conzzeta AG	CON SE	3297.866667	0.003032263	1.00%
Buy	Cash		1	30.00000000	3.00%

Contact: UBS AG, P.O. Box, 8098 Zürich

Private Investors: Please contact your client advisor or send an email to keyinvest@ubs.com

Internet: www.ubs.com/keyinvest

Product Hotline: +41-44-239 76 76*

Investors outside of Switzerland should consult their local client advisors.

Please note that calls made to the numbers marked with an asterisk (*) may be recorded. Should you call one of these numbers, we shall assume that you consent to this business practice.